Searchable abstracts of presentations at key conferences in endocrinology

ea0044ep90 | (1) | SFEBES2016

Thyroid dysfunction caused by three different Tyrosine Kinase inhibitors (TKI)

Sivappriyan Siva , Clarke Viktoria , Kumar Jesse , Joshi Supriya

Tyrosine kinase inhibitors (TKIs) are relatively new therapy drugs used for the treatment of metastatic cancers including Renal cell carcinoma (RCC), gastrointestinal stromal tumours, thyroid and neuroendocrine tumours. They block vascular endothelial growth factor and other growth factors Thyroid dysfunction is often a side effect of this treatment. A close monitoring of thyroid hormone levels is a necessity.We have a case of a 69-year-old lady with RCC...

ea0044ep96 | (1) | SFEBES2016

Acute confusion in a cyclist

Giannopoulou Angeliki , Hancock Sian , Kumar Senthil , Mallipedhi Akhila , Rice Sam

A 46-year-old male was brought to the hospital by his uncle as he was found to be acutely confused and agitated ‘talking rubbish’ and giggling inappropriately. Last time he was seen well was 3 days ago. He was a cyclist who lived alone and his past medical history included Graves’ disease and AF. He was on propranolol, carbimazole and warfarin. A month ago he needed admission to a different hospital after falling off his bike. At that time he also developed conf...

ea0041gp164 | Pituitary - Clinical (1) | ECE2016

Ipilimumab-induced hypophysitis in melanoma patients: a single centre experience

Kumar Mohit , Bowyer Samantha , Lorigan Paul , Higham Claire , Trainer Peter

Ipilimumab, a monoclonal antibody against CTLA-4, is licenced for the treatment of metastatic melanoma (dose of 3 mg/kg for four cycles intravenously). It can cause immune-related adverse reactions (IRAEs) in multiple organs, with hypophysitis the most common endocrine IRAE. We carried out a retrospective analysis of 171 ipilimumab-treated patients in one centre for endocrinopathies.Results: Nine cases (six female, mean age 64 years, range 42–76) of...

ea0039ep11 | Adrenal | BSPED2015

A case of acute muscular weakness from Ectopic ACTH secreting Neuroendocrine Tumour of the Thymus

Pan Daniel , Spiking Joseph , Gupta Rahul Kumar , Agrawal Alok

A 16 year old previously healthy boy from Manipur, India was admitted with rapid onset quadraparesis, vomiting and diarrhoea, on a background 3 month history of increasing facial puffiness and progressive widespread rash. Investigations revealed hyperglycaemia, hypokalaemia and a raised ESR. The basal serum cortisol was 103 μg/dl (n=7–22 μg/dl) at 0800 h. 24-h urinary free cortisol failed to suppress with 8 mg of dexamethasone. Plasma ACTH and serum ald...

ea0039ep25 | Diabetes | BSPED2015

Using co-production and graphic facilitation to improve patient experience in type 1 diabetes mellitus

Blackstock Sarah , Hopkins Julia , Ria Matteo , Kumar Priya

Introduction: Co-production refers to working in partnership with service-users to improve provision of services. Increasing evidence highlights that co-production can improve health care and result in financial savings. Service-users are involved in defining the problem or need, creating the solution, delivering it, and evaluating it. This approach demands longer-term engagement by service-providers but leads to sustainable change. Graphic facilitation is the use of large-sca...

ea0059p115 | Neoplasia, cancer & late effects | SFEBES2018

Could this be the tip of the iceberg? Endocrine dysfunction of immune checkpoint inhibitors in Kent Regional Oncology Service

Wang Tian , Anandappa Samantha , Kumar Jesse , Sivappriyan Siva

Aim: Baseline clinical and biochemical endocrine assessment at the start of immune checkpoint treatment and each treatment cycle is important given the treatable nature of it. Also given the improvements in survival of these patients necessitate further longterm screening. Our study was to look at various aspects of this screening with a view to improve our knowledge and also patient care.Methods: Using an excel database, a retrospective data collection ...

ea0059p177 | Reproduction | SFEBES2018

Naringenin inhibits progression, proliferation and induces apoptosis via ROS generation in endometriotic lesions in rats

Kapoor Radhika , Kumar Sirohi Vijay , Gupta Kanchan , Dwivedi Anila

Endometriosis is one of the commonly occurring disorders of reproductive women, which represents attachment of functional endometrial cells and tissue outside the uterine cavity, culminates into infertility. This invasive disorder is still under quest for novel treatment strategies. Naringenin is a plant-derived flavonoid having anti-proliferative, anti-inflammatory, and anti-angiogenic properties in chronic and metabolic diseases. The study was planned with an objective to de...

ea0037gp.09.05 | Nuclear receptors and signalling | ECE2015

Neuroprotective effects of 17β-oestradiol: a therapeutic potential drug for Alzheimer's disease

Kumar Pardeep , Kale R K , Baquer N Z

Objectives: Alzheimer’s disease (AD) is the most common form of dementia in the elderly. AD is characterized by the presence of amyloid plaques which are formed from deposits of β-amyloid protein (Ab). These changes increase during menopausal condition in females when the level of oestradiol (E2) is decreased. The aim of the present study was to determine the effect of neuropeptide, neurokinin B (NKB) and amyloid beta fragment Aβ (25–35) on E<sub...

ea0037ep398 | Diabetes (pathiophysiology &amp; epitemiology) | ECE2015

Modulation of metabolic parameters and antioxidant enzymes in diabetic ageing female rat brains: beneficial role of metformin

Kumar Pardeep , Kale R K , Baquer N Z

Objective: The objective of this study was to investigate beneficial effects of metformin on membrane bound enzymes (monoamine oxidase, Na+K+ ATPse) and antioxidant enzymes (sueroxidase dismutase and glutathione S-transferases), lipid peroxidation, neurolipofuscin, and DNA degradation in diabetic aging female rats.Methods: Young (3 months) adult (12 months) and aged (24 months) rats will be diabetic by using alloxan monohyd...

ea0037ep636 | Obesity and cardiovascular endocrinology | ECE2015

The use of intermittent 7.5 mg tolvaptan on an out-patient basis for SIADH: a retrospective audit from a tertiary cancer hospital

Kumar Mohit , Pichaipillai Lakshminarayanan , Trainer Peter , Higham Claire

Tolvaptan (a V2 receptor antagonist) is licensed for correction of hyponatraemia in patients with SIADH at an initial dose of 15 mg od. Data in oncology patients with SIADH suggest 7.5 mg can safely and effectively increase sodium levels where 15 mg can on occasion lead to too rapid a correction. Recommendations suggest a repeat sodium taken at 4–6 h. We retrospectively assessed the safety and efficacy of intermittent out-patient dosing with 7.5 mg tolv...